Die aktuelle Sarkopenie-Definition

 

 Buy Article Permissions and Reprints

Abstract

Sarcopenia is characterized by a generalized loss of muscle function, strength and mass and is codable in Germany since 2018 in the ICD-10-GM (M62.50). For screening in primary care, it is possible to determine muscle function and strength by means of a sarcopenia questionnaire (SARC-F) as a self-filler with 5 questions of restrictions. With an increased score of 4 and higher, an examination of the musculature and a determination of the skeletal muscle mass index should be performed via dual energy X-ray absorption measurement (DXA) or bioelectric impedance analysis (BIA).

If hand and/or leg strength is limited, the patient has probable sarcopenia and, according to the current revised version of the European consensus on sarcopenia, therapy can already be started and the cause clarified. A DXA or BIA examination confirms the diagnosis of sarcopenia by a lowered skeletal muscle index. A follow-up examination is recommended to differentiate between acute or chronic sarcopenia and to assess the progression of the disease. The severity of the disease is defined by additional examinations such as gait speed, timed up and go test (TUG) and/or short physical performance battery (SPPB). Patients with sarcopenia suffer from increasing immobility and disability and have an increased risk of falls, fractures and mortality. Frequently, co-morbidities should be clarified in all affected patients.

Publication History

Article published online:
09 September 2020

© Georg Thieme Verlag KG
Stuttgart · New York

• Literatur

• 1 Rosenberg IH. Summary Comment. Am J Clin Nutr 1989; 50: 1231-1233
  CrossrefPubMedGoogle Scholar
• 2 Cruz-Jentoft AJ, Baeyens JP, Bauer JM. et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing 2010; 39: 412-423
  CrossrefPubMedGoogle Scholar
• 3 Cruz-Jentoft AJ, Sayer AA. Sarcopenia. Lancet 2019; 393: 2636-2646 . doi:10.1016/S0140-6736(19)31138-9
  CrossrefPubMedGoogle Scholar
• 4 Beaudart C, Zaaria M, Pasleau F. et al Health Outcomes of Sarcopenia: A Systematic Review and Meta-Analysis. PLoS One 2017; 12: e0169548 . doi:10.1371/journal.pone.0169548
  CrossrefPubMedGoogle Scholar
• 5 Phillips A, Strobl R, Vogt S. et al. Sarcopenia is associated with disability status-results from the KORA-Age study. Osteoporos Int 2017; 28: 2069-2079
  CrossrefPubMedGoogle Scholar
• 6 Malmstrom TK, Morley JE. SARC-F: A simple questionnaire to rapidly diagnose sarcopenia. J Am Med Dir Assoc 2013; 14: 531-532
  CrossrefPubMedGoogle Scholar
• 7 Malmstrom TK, Miller DK, Simonsick EM. et al SARC-F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes. J Cachexia Sarcopenia Muscle 2016; 7: 28-36 . doi:10.1002/jcsm.12048
  CrossrefPubMedGoogle Scholar
• 8 Bahat G, Yilmaz O, Oren MM. Cross-cultural adaptation and validation of the SARC-F to assess sarcopenia: methodological report from European Union Geriatric Medicine Society Sarcopenia Special Interest Group. Eur Geriatr Med 2018; 9: 23-28
  CrossrefPubMedGoogle Scholar
• 9 Ida S, Kaneko R, Murata K. SARC-F for Screening of Sarcopenia Among Older Adults: A Meta-analysis of Screening Test Accuracy. J Am Med Dir Assoc 2018; 19: 685-689 . doi:10.1016/j.jamda.2018.04.001
  CrossrefPubMedGoogle Scholar
• 10 Drey M, Ferrari U, Schraml M. et al German Version of SARC-F: Translation, Adaption, and Validation. J Am Med Dir Assoc 2020; 21: 747-751 . doi:10.1016/j.jamda.2019.12.011
  CrossrefPubMedGoogle Scholar
• 11 Cruz-Jentoft AJ, Bahat G, Bauer J. et al. Sarcopenia: Revised European consensus on definition and diagnosis. Age Ageing 2019; 48: 16-31
  CrossrefPubMedGoogle Scholar
• 12 Sergi G, De Rui M, Veronese N. et al. Assessing appendicular skeletal muscle mass with bioelectrical impedance analysis in free-living Caucasian older adults. Clin Nutr 2015; 34: 667-673
  CrossrefPubMedGoogle Scholar
• 13 Gould H, Brennan SL, Kotowicz MA. et al Total and Appendicular Lean Mass Reference Ranges for Australian Men and Women: The Geelong Osteoporosis Study. Calcif Tissue Int 2014; 94: 363-372 . doi:10.1007/s00223-013-9830-7
  CrossrefPubMedGoogle Scholar
• 14 Bischoff HA, Stähelin HB, Monsch AU. et al Identifying a cut-off point for normal mobility: a comparison of the timed “up and go” test in community-dwelling and institutionalised elderly women. Age Ageing 2003; 32: 315-320 . doi:10.1093/ageing/32.3.315
  CrossrefPubMedGoogle Scholar
• 15 Cruz-Jentoft AJ, Bahat G, Bauer J. et al Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019; 48 (04) 601 ; doi:10.1093/ageing/afz046. Erratum for: Age Ageing. 2019 Jan 1; 48(1):16–31. PMID: 31081853; PMCID: PMC6593317
  PubMedGoogle Scholar
• 16 Dávalos-Yerovi V, Marco E, Sánchez-Rodríguez D. et al. Sarcopenia According to the Revised European Consensus on Definition and Diagnosis (EWGSOP2) Criteria Predicts Hospitalizations and Long-Term Mortality in Rehabilitation Patients With Stable Chronic Obstructive Pulmonary Disease. J Am Med Dir Assoc 2019; 20: 1047-1049
  CrossrefPubMedGoogle Scholar
• 17 Lewis R, Gómez Álvarez CB, Rayman M. et al Strategies for optimising musculoskeletal health in the 21st century. BMC Musculoskelet Disord 2019; 20: 164 . doi:10.1186/s12891-019-2510-7
  CrossrefPubMedGoogle Scholar